You are here: Industry Insights > rare disease

News List

Licensing agreement deals decline in rare diseases space: GlobalData expresspharma
August 10, 2020
Big pharma companies are searching for innovative biotechs to invest in the rare diseases space.
Evox and Takeda sign deal to collaborate on rare disease treatments europeanpharmaceuticalreview
April 02, 2020
In an $882 million deal, Evox and Takeda will partner to develop and manufacture treatments and drug delivery systems for rare diseases.
Takeda enters rare disease alliance with Evox Therapeutics pharmaceutical-technology
March 30, 2020
Takeda Pharmaceutical has entered a multi-target alliance with biotechnology company Evox Therapeutics to develop protein replacement and mRNA therapies for rare diseases.
Pfizer acquires rare disease biotech Therachon for $340m pharmaceutical-technology
July 03, 2019
Pfizer has announced it has completed its acquisition of US-based Therachon, a clinical stage biotechnology company focusing on rare diseases; the acquisition was first initiated in early May 2019.
Fibrocell, Castle Creek ink rare disease gene therapy pacts fiercebiotech
April 17, 2019
Fibrocell is enlisting Castle Creek Pharma’s help to push its midphase gene therapy for a rare genetic disorder through the clinic and onto the market.
Takeda, Microsoft rare disease partnership publishes diagnosis road map fiercepharma
March 03, 2019
Now that Takeda has swallowed Shire, it's doubling down on rare disease. And one way it's doing that is through a partnership with Microsoft and Eurodis, which has delivered a road map to shorten time to diagnosis and detailed three pilot programs underwa
Mendelian gets £500,000 for rare disease screening tech pharmaphorum
February 26, 2019
UK health technology startup Mendelian has received a £500,000 grant from a government agency to build products that will help GPs identify patients with rare or hard to diagnose conditions and diseases.
Ipsen to buy rare disease firm Clementia for up to $1.31bn pharmaphorum
February 26, 2019
France’s Ipsen has agreed to buy Canadian rare diseases biotech Clementia Pharmaceuticals in a deal worth up to $1.31 billion.
Expect more transparency around pharma's advocacy group partnerships in 2019 fiercepharma
December 24, 2018
Advocacy groups and pharma companies often work hand in hand, especially in rare diseases. This year, however, saw some of the shine wear off of those close relationships as politicians and the media raised red flags over payments from pharma companies.
Expect more transparency around pharma's advocacy group partnerships in 2019 fiercepharma
December 24, 2018
Advocacy groups and pharma companies often work hand in hand, especially in rare diseases. This year, however, saw some of the shine wear off of those close relationships as politicians and the media raised red flags over payments from pharma companies.

Previous page 1 2 3 4 5 Next page